Clinical Trials
Apixaban has an extensive portfolio of numerous clinical trials spanning Phase 1 through Phase 4, supported by pharmaceutical sponsors like Bristol-Myers Squibb alongside academic institutions like the Mayo Clinic. These studies encompass conditions such as atrial fibrillation, venous thromboembolism, acute coronary syndrome, left ventricular thrombosis, liver cirrhosis, surgical bleeding, and oncological thromboprophylaxis in glioblastoma and bladder cancer. Currently exhibiting statuses ranging from actively recruiting and completed to active not recruiting and withdrawn, these clinical trials highlight the drug's broad therapeutic scope.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07005024 | RECRUITING | Cancer; VTE (Venous Thromboembolism) |
University of Vermont |
2025-10-17 | PHASE3 |
| NCT06953726 | RECRUITING | Atrial Fibrillation |
VA Office of Research and Development |
2026-06-01 | PHASE4 |
| NCT06953778 | NOT_YET_RECRUITING | Atrial Fibrillation |
VA Office of Research and Development |
2027-03-08 | |
| NCT07493304 | RECRUITING | Venous Thromboembolism (VTE) |
Regeneron Pharmaceuticals |
2026-08-31 | PHASE3 |
| NCT07753200 | RECRUITING | Atrial Fibrillation (AF); Coronary Arterial Disease (CAD) |
Samsung Medical Center |
2026-07-20 | PHASE4 |
| NCT06729034 | NOT_YET_RECRUITING | Venous Malformation, Low Flow; Anticoagulants |
Oslo University Hospital |
2025-02-01 | PHASE2 |
| NCT07726693 | NOT_YET_RECRUITING | Liver Cirrhosis |
University College, London |
2026-07-15 | PHASE3 |
| NCT06869083 | NOT_YET_RECRUITING | Atrial Fibrillation on Apixaban Treatment |
Yonsei University |
2025-03 | |
| NCT06650501 | RECRUITING | Staphylococcus Aureus Endocarditis; Staphylococcus Aureus Septicemia; Staphylococcus Aureus Bacteremia; Staphylococcus Aureus Bloodstream Infection; S. Aureus Bacteremia; S. Aureus Bloodstream Infection |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2026-01-15 | PHASE4 |
| NCT06603870 | RECRUITING | Venous Thromboembolism; Cancer; Upper Extremity Deep Vein Thrombosis; Catheter-Related Infections |
Ottawa Hospital Research Institute |
2024-12-19 | PHASE4 |
| NCT06864052 | NOT_YET_RECRUITING | Stroke; Atrial Fibrillation |
Ewha Womans University Seoul Hospital |
2025-03-01 | |
| NCT07160686 | NOT_YET_RECRUITING | Thromboprophylaxis |
University of Birmingham |
2026-03-02 | PHASE3 |
| NCT07626411 | RECRUITING | Atrial Fibrillation (AF) |
Regeneron Pharmaceuticals |
2026-08-10 | PHASE3 |
| NCT07471139 | NOT_YET_RECRUITING | LVAD (Left Ventricular Assist Device) Thrombosis; Heart Failure; Bleeding; Thrombosis; Artery; Stroke; Heart Transplant |
Columbia University |
2026-08 | PHASE3 |
| NCT07237308 | NOT_YET_RECRUITING | Stroke; Ischemic; Atrial Fibrillation; Intracrnaial Arterioscelrosis; Arteriosclerosis |
Yonsei University |
2025-12 | PHASE4 |
| NCT03243175 | RECRUITING | Intracerebral Hemorrhage; Atrial Fibrillation; Microhaemorrhage |
University Hospital, Lille |
2019-01-17 | PHASE3 |
| NCT06486792 | RECRUITING | Stroke; Ischemic Stroke; Cerebral Infarction; Atrial Fibrillation |
Assistance Publique - Hôpitaux de Paris |
2025-06-18 | PHASE4 |
| NCT04666454 | RECRUITING | Takotsubo Syndrome |
Vastra Gotaland Region |
2020-12-14 | PHASE4 |
| NCT06523959 | RECRUITING | Venous Thromboembolism; Bleeding |
Clinical Urology and Epidemiology Working Group |
2024-06-06 | PHASE4 |
| NCT06370273 | RECRUITING | Thrombosis; Injury Leg |
Queen Mary University of London |
2024-11-12 | PHASE3 |
| NCT07746882 | NOT_YET_RECRUITING | Stroke; Acute Ischemic Stroke |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2026-08-15 | PHASE3 |
| NCT07709780 | RECRUITING | Left Ventricular Thrombus |
University of Arizona |
2026-06-22 | PHASE3 |
| NCT06515730 | RECRUITING | Left Ventricular Thrombus; Acute Myocardial Infarction |
Karolinska Institutet |
2025-04-08 | PHASE4 |
| NCT07404345 | NOT_YET_RECRUITING | Hemodialysis Access Failure; Kidney Disease, End-Stage; Hemodialysis Catheter |
Hospital Civil de Guadalajara |
2026-03-01 | PHASE4 |
| NCT05701917 | RECRUITING | Venous Thromboembolism; Deep Venous Thrombosis; Post-Thrombotic Syndrome |
Inari Medical |
2023-01-06 | |
| NCT07434661 | NOT_YET_RECRUITING | Valve Disease, Heart; Atrial Fibrillation (AF); Valve Replacement Surgery; Aortic Valve Surgery; Mitral Valve Annuloplasty; Mitral Valve Repair; Mitral Valve Surgery |
Meshalkin Research Institute of Pathology of Circulation |
2026-02 | PHASE3 |
| NCT04642430 | RECRUITING | Atrial Fibrillation |
Ottawa Hospital Research Institute |
2021-07-06 | PHASE4 |
| NCT05679024 | RECRUITING | Chronic Kidney Diseases; Atrial Fibrillation; Stroke; Intracerebral Hemorrhage; Major Bleed; Cardiovascular Complication; Death; Kidney Transplant; Complications; Thromboses, Venous |
Region Stockholm |
2023-02-17 | PHASE3 |
| NCT06957366 | RECRUITING | Atrial Fibrillation (AF); VTE |
McMaster University |
2025-04-01 | |
| NCT07246005 | NOT_YET_RECRUITING | Left Ventricular Thrombus |
Queen Mary University of London |
2026-12-01 | PHASE2 |
| NCT07713875 | NOT_YET_RECRUITING | Venous Thromboembolism (VTE); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Spine Metastasis |
James Bayley |
2026-08 | PHASE4 |
| NCT06045858 | NOT_YET_RECRUITING | Atrial Fibrillation; Peritoneal Dialysis Complication |
University Hospital, Caen |
2024-10-30 | PHASE3 |
| NCT03129490 | ACTIVE_NOT_RECRUITING | Atrial Fibrillation; Atrial Flutter |
Herlev and Gentofte Hospital |
2023-04-01 | PHASE4 |
| NCT07461545 | RECRUITING | Cirrhosis; Splenectomy; Portal Vein Thrombosis; Hypertension, Portal |
Northern Jiangsu People's Hospital |
2026-04-01 | |
| NCT07461532 | RECRUITING | Cirrhosis; Splenectomy; Portal Vein Thrombosis; Hypertension, Portal |
Northern Jiangsu People's Hospital |
2026-04-01 | |
| NCT07189897 | RECRUITING | Venous Thromboembolism; Head and Neck Cancer |
Kiranya Arnold |
2025-10 | PHASE4 |
| NCT05198960 | RECRUITING | Polycythemia Vera; Essential Thrombocythemia; Prefibrotic/Early Primary Myelofibrosis; JAK2 V617F; High-risk Patients |
University Hospital, Brest |
2022-07-13 | PHASE3 |
| NCT06886516 | RECRUITING | Deep Vein Thrombosis; Pulmonary Embolism and Thrombosis; Thrombocytopenia; Recurrent Venous Thromboembolism |
Rushad Patell |
2025-02-28 | EARLY_PHASE1 |
| NCT05735639 | RECRUITING | Venous Thromboembolism; Varicose Veins |
Imperial College London |
2024-01-22 | PHASE4 |
| NCT07716332 | NOT_YET_RECRUITING | Postpartum; DVT Prophylaxis |
Ron Beloosesky MD |
2026-07-01 | |
| NCT07521332 | RECRUITING | Cirrhosis; Esophageal and Gastric Varices; Ascites; Hepatic Encephalopathy; Portal Vein Thrombosis; Portal Hypertension |
Asian Institute Of Medical Sciences |
2026-04-01 | PHASE4 |
| NCT03907046 | RECRUITING | Intracerebral Hemorrhage; Atrial Fibrillation |
Yale University |
2020-01-28 | PHASE3 |
| NCT03129555 | ACTIVE_NOT_RECRUITING | Deep Vein Thrombosis; Pulmonary Embolism |
Herlev and Gentofte Hospital |
2023-04-01 | PHASE4 |
| NCT06474182 | RECRUITING | Multiple Myeloma; Total Knee Replacement |
Centre Hospitalier Universitaire de Saint Etienne |
2025-09-15 | |
| NCT07015905 | RECRUITING | Venous Thromboembolism (VTE) |
Regeneron Pharmaceuticals |
2025-06-25 | PHASE3 |
| NCT07175428 | RECRUITING | Atrial Fibrillation (AF) |
Regeneron Pharmaceuticals |
2025-10-20 | PHASE2 |
| NCT05683808 | RECRUITING | Glioblastoma; Astrocytoma; Venous Thromboembolism |
University of Vermont Medical Center |
2023-01-16 | PHASE2 |
| NCT05757869 | ACTIVE_NOT_RECRUITING | Atrial Fibrillation |
Janssen Research & Development, LLC |
2023-04-11 | PHASE3 |
| NCT04874428 | RECRUITING | Liver Cirrhosis |
Insel Gruppe AG, University Hospital Bern |
2021-05-19 | PHASE1 |
| NCT04981327 | NOT_YET_RECRUITING | Deep Vein Thrombosis |
University Hospital, Geneva |
2022-09-01 | PHASE3 |
| NCT04007289 | ACTIVE_NOT_RECRUITING | Intrahepatic Non Cirrhotic Portal Hypertension |
Assistance Publique - Hôpitaux de Paris |
2019-06-24 | PHASE3 |
| NCT04432220 | RECRUITING | Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation |
Yonsei University |
2020-07-28 | PHASE4 |
| NCT07559942 | RECRUITING | Endstage Renal Disease; Direct Oral Anticoagulants (DOACs); Arteriovenous Fistula; Arteriovenous Fistula Occlusion |
Combined military hospital lahore |
2026-01-01 | |
| NCT07312851 | COMPLETED | Healthy Participants |
AstraZeneca |
2026-01-19 | PHASE1 |
| NCT05035277 | COMPLETED | Aortic Stenosis |
Oslo University Hospital |
2021-12-04 | PHASE3 |
| NCT05869591 | RECRUITING | Liver Cirrhosis |
Centre Hospitalier Universitaire Vaudois |
2024-01-18 | PHASE2 |
| NCT07270263 | RECRUITING | Lymphoma; Leukemia; Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma; Venous Thromboembolic Disease; VTE (Venous Thromboembolism); PE - Pulmonary Embolism; Hematologic Malignacies |
Medical University of Gdansk |
2024-11-22 | |
| NCT06449469 | ACTIVE_NOT_RECRUITING | Aortic Valve Stenosis; Cardiovascular Diseases; Heart Diseases; Heart Valve Diseases; Valve Disease, Aortic |
Rigshospitalet, Denmark |
2021-05-01 | |
| NCT07265466 | RECRUITING | Drug Drug Interaction (DDI) |
Onconic Therapeutics Inc. |
2025-11-17 | PHASE1 |
| NCT05171049 | TERMINATED | Venous Thromboembolism; Deep Venous Thrombosis; Pulmonary Embolism |
Anthos Therapeutics, Inc. |
2022-05-05 | PHASE3 |
| NCT06243510 | COMPLETED | Bladder Cancer |
Abramson Cancer Center at Penn Medicine |
2023-11-24 | |
| NCT07774273 | COMPLETED | Pulmonary Embolism Acute; Venous Thromboembolism (VTE) |
Combined military hospital lahore |
2021-01-01 | |
| NCT03935451 | UNKNOWN | IBD; Venous Thromboembolism; Crohn Disease; Ulcerative Colitis; Pulmonary Embolism; Colorectal Disorders |
McMaster University |
2021-09-01 | EARLY_PHASE1 |
| NCT06862726 | ENROLLING_BY_INVITATION | Non Valvular Atrial Fibrillation |
Les Laboratoires des Médicaments Stériles |
2024-12-01 | PHASE4 |
| NCT06903845 | RECRUITING | Atrial Fibrillation |
Dong-Ju Choi |
2025-03-01 | |
| NCT06184113 | UNKNOWN | Aortic Valve Replacement; Antithrombotic Therapy; Bioprosthetic Valve Thrombosis; Rapid Deployment Valves |
Clinical Hospital Centre Zagreb |
2023-12 | PHASE4 |
| NCT06742567 | RECRUITING | Acute Myocardial Infarction of Anterior Wall; Left Ventricular Thrombus; Prophylaxis |
National Institute of Cardiovascular Diseases, Pakistan |
2024-12-02 | PHASE3 |
| NCT05687448 | NOT_YET_RECRUITING | Aortic Valve Disease |
Assistance Publique - Hôpitaux de Paris |
2025-09 | PHASE3 |
| NCT03568890 | ACTIVE_NOT_RECRUITING | Left Atrial Appendage Closure; Thrombosis; Stroke; TIA; Bleeding |
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec |
2018-09-01 | PHASE4 |
| NCT07132515 | RECRUITING | Cirrhosis; HCC - Hepatocellular Carcinoma; Portal Vein Thrombosis |
Mansoura University |
2023-08-15 | PHASE4 |
| NCT05484557 | RECRUITING | Spinal Cord Injuries; Spinal Diseases |
Loewenstein Hospital |
2023-09-06 | |
| NCT03266783 | COMPLETED | Venous Thromboembolism |
Ottawa Hospital Research Institute |
2017-12-13 | PHASE4 |
| NCT03961334 | UNKNOWN | Stroke, Ischemic |
University of Zurich |
2019-12-05 | PHASE3 |
| NCT06689436 | COMPLETED | Random Allocation; Intermittent Fasting; Enteral Feeding |
TAHO Pharmaceuticals Ltd. |
2024-11-16 | PHASE2 |
| NCT04344717 | UNKNOWN | Short Bowel Syndrome; Anticoagulation |
Universitaire Ziekenhuizen KU Leuven |
2020-12-20 | PHASE4 |
| NCT03463317 | COMPLETED | Atrial Fibrillation |
Charite University, Berlin, Germany |
2018-02-28 | PHASE4 |
| NCT06388239 | UNKNOWN | Healthy Volunteer |
International Bio service |
2024-08-26 | PHASE1 |
| NCT03692065 | COMPLETED | Cancer-associated Thrombosis |
Assistance Publique - Hôpitaux de Paris |
2018-10-11 | PHASE3 |
| NCT06531122 | UNKNOWN | Cerebral Venous Thrombosis |
Kafrelsheikh University |
2021-08-01 | PHASE3 |
| NCT06551415 | UNKNOWN | Cerebral Venous Sinus Thrombosis |
Kafrelsheikh University |
2021-08-01 | PHASE3 |
| NCT06372483 | ACTIVE_NOT_RECRUITING | Coagulation Disorder |
VarmX B.V. |
2024-02-21 | PHASE1 |
| NCT06388239 | Not yet recruiting | Healthy Volunteer |
International Bio service |
2024-08-26 | Phase 1 |
| NCT05973188 | UNKNOWN | Left Ventricular Thrombus |
Peshawar Institute of Cardiology |
2023-05-01 | PHASE4 |
| NCT05419583 | COMPLETED | Myocardial Infarction Type 2 |
University of Edinburgh |
2022-11-14 | |
| NCT04504318 | COMPLETED | Venous Thromboembolism |
Stanford University |
2020-08-12 | PHASE1; PHASE2 |
| NCT03996772 | COMPLETED | Atrial Fibrillation; Intracerebral Hemorrhage |
Imperial College London |
2019-06-03 | PHASE3 |
| NCT04850378 | COMPLETED | Nephrotic Syndrome; Thromboembolic Disease |
University of Aarhus |
2021-03-25 | PHASE1; PHASE2 |
| NCT02464969 | COMPLETED | Venous Thromboembolism |
Bristol-Myers Squibb |
2015-11-22 | PHASE4 |
| NCT06205615 | COMPLETED | Wound Bleeding |
Bio 54, LLC |
2024-01-24 | PHASE2 |
| NCT04974684 | COMPLETED | LVAD (Left Ventricular Assist Device) Thrombosis |
Institute for Clinical and Experimental Medicine |
2022-04-01 | |
| NCT05643573 | TERMINATED | Prevention of Stroke or Systemic Embolism; Atrial Fibrillation |
Bayer |
2022-12-05 | PHASE3 |
| NCT04801940 | UNKNOWN | Covid19 |
Cambridge University Hospitals NHS Foundation Trust |
2021-05-19 | PHASE3 |
| NCT05093504 | TERMINATED | Hemorrhage, Surgical; Hemorrhage Postoperative; Blood Loss, Surgical; Blood Loss, Postoperative |
CytoSorbents, Inc |
2021-12-27 | |
| NCT05869591 | Recruiting | Liver Cirrhosis |
Centre Hospitalier Universitaire Vaudois |
2024-01-18 | Phase 2 |
| NCT04645550 | COMPLETED | Cirrhosis; Splenectomy; Status; Venous Thrombosis; Hypertension, Portal |
Northern Jiangsu People's Hospital |
2020-11-22 | PHASE4 |
| NCT05491460 | UNKNOWN | Anticoagulant Therapy |
Doasense GmbH |
2022-07-01 | PHASE1 |
| NCT04168203 | COMPLETED | Deep Vein Thrombosis; Pulmonary Embolism; Venous Thromboembolism |
Brigham and Women's Hospital |
2021-03-01 | PHASE4 |
| NCT04243122 | COMPLETED | Myeloproliferative Neoplasm (MPN); Essential Thrombocythemia (ET); JAK2 Mutation; Polycythemia Vera (PV); Primary Myelofibrosis; Venous Thromboembolism (VTE) |
Ottawa Hospital Research Institute |
2021-02-17 | PHASE2 |
| NCT01938248 | COMPLETED | Atrial Fibrillation; Stroke |
Population Health Research Institute |
2015-05 | PHASE4 |
| NCT04865978 | COMPLETED | Heart Failure |
Palak Shah |
2021-12-14 | PHASE2 |
| NCT04278729 | COMPLETED | Nephrotic Syndrome; Membranous Nephropathy |
University of North Carolina, Chapel Hill |
2021-04-14 | PHASE1 |
| NCT05723510 | COMPLETED | Healthy |
HK inno.N Corporation |
2023-03-06 | PHASE1 |
| NCT04891861 | UNKNOWN | Anticoagulants; Increased |
University of Texas at Austin |
2021-07-01 | PHASE3 |
| NCT05304455 | COMPLETED | Cirrhosis; Splenectomy; Venous Thrombosis; Hypertension, Portal |
Northern Jiangsu People's Hospital |
2022-04-01 | |
| NCT03192215 | TERMINATED | Stroke |
Columbia University |
2018-01-19 | PHASE3 |
| NCT06043297 | COMPLETED | Antithrombic Drug |
Humanis Saglık Anonim Sirketi |
2023-02-23 | PHASE1 |
| NCT05152420 | COMPLETED | Coagulation Disorder |
VarmX B.V. |
2021-10-29 | PHASE1 |
| NCT04002011 | WITHDRAWN | Anticoagulant-induced Bleeding |
Laval University |
2022-03-09 | PHASE2 |
| NCT05683808 | Not yet recruiting | Glioblastoma|Astrocytoma|Venous Thromboembolism |
University of Vermont Medical Center|Dartmouth-Hitchcock Medical Center|MaineHealth |
2023-01-16 | Phase 2 |
| NCT03987711 | COMPLETED | Atrial Fibrillation; End Stage Renal Failure on Dialysis |
Unity Health Toronto |
2019-12-10 | PHASE2 |
| NCT04512079 | COMPLETED | COVID-19; SARS-CoV-2 |
Valentin Fuster |
2020-09-08 | PHASE4 |
| NCT05995119 | COMPLETED | Healthy Volunteers; Fasting; Fed |
TAHO Pharmaceuticals Ltd. |
2022-12-05 | EARLY_PHASE1 |
| NCT03148457 | COMPLETED | Ischaemic Stroke |
Insel Gruppe AG, University Hospital Bern |
2017-11-06 | |
| NCT04952792 | COMPLETED | Atrial Fibrillation; Hemodialysis Complication |
Hospital Universitari de Bellvitge |
2021-05-20 | PHASE2 |
| NCT04142658 | TERMINATED | Aortic Valve Disease; Aortic Valve Stenosis; Aortic Valve Failure |
Artivion Inc. |
2020-05-01 | PHASE3 |
| NCT04006093 | COMPLETED | Chronic Renal Insufficiency; Peritoneal Dialysis |
University Hospital, Caen |
2019-12-08 | PHASE1 |
| NCT03864406 | COMPLETED | Healthy Volunteers |
National Institutes of Health Clinical Center (CC) |
2019-06-04 | PHASE1 |
| NCT04696120 | UNKNOWN | Heart Failure; Sinus Rhythm; Cerebrovascular Disease |
Korea University Guro Hospital |
2021-03-02 | PHASE2 |
| NCT02933697 | COMPLETED | Atrial Fibrillation; End-stage Kidney Disease |
Atrial Fibrillation Network |
2017-06-20 | PHASE3 |
| NCT04650087 | COMPLETED | Covid19 |
Thomas L. Ortel |
2021-02-15 | PHASE3 |
| NCT03080883 | COMPLETED | Cerebral Vein Thrombosis; Deep Vein Thrombosis; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Pulmonary Embolism; Splanchnic Vein Thrombosis |
Academic and Community Cancer Research United |
2017-07-14 | PHASE3 |
| NCT05088928 | UNKNOWN | COVID-19 |
Scotmann Pharmaceuticals |
2022-03-01 | PHASE2 |
| NCT04746339 | TERMINATED | Covid19; Thrombosis |
Brazilian Clinical Research Institute |
2021-03-04 | PHASE4 |
| NCT04489849 | UNKNOWN | Hemodialysis Access Failure |
National Taiwan University Hospital Hsin-Chu Branch |
2020-03-14 | PHASE4 |
| NCT04229264 | UNKNOWN | Critical Limb Ischemia |
Science Valley Research Institute |
2020-01-09 | PHASE3 |
| NCT02664155 | TERMINATED | Renal Insufficiency |
Centre Hospitalier Universitaire de Saint Etienne |
2016-10-19 | PHASE3 |
| NCT02945280 | TERMINATED | Deep Venous Thrombosis; Upper Extremity Deep Venous Thrombosis; Thrombus; Venous Thromboembolism; Deep Vein Thrombosis |
Intermountain Health Care, Inc. |
2017-02-22 | PHASE4 |
| NCT04479579 | COMPLETED | Neoplasms Malignant; Surgery; Venous Thromboembolism; Prophylaxis; Adherence, Medication |
McMaster University |
2021-02-22 | PHASE4 |
| NCT02981472 | COMPLETED | Thrombosis |
Bristol-Myers Squibb |
2017-01-19 | PHASE2 |
| NCT04218266 | COMPLETED | Atrial Fibrillation (AF) |
Bayer |
2020-01-30 | PHASE2 |
| NCT05208398 | COMPLETED | Left Ventricular Thrombus |
Saud Al Babtain Cardiac Center |
2018-02-18 | PHASE3 |
| NCT03139487 | UNKNOWN | Cancer-associated Thrombosis; Esophageal Cancer; Stomach Cancer; Hepatocellular Carcinoma; Pancreatic Cancer; Duodenal Cancer; Esophagogastric Junction Cancer; Malignant Gastrointestinal Stromal Tumor; Ampulla of Vater Cancer; Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer) |
Asan Medical Center |
2017-08-07 | PHASE2 |
| NCT03678506 | TERMINATED | Venous Thromboembolism; Anticoagulants |
Arianna Anticoagulazione Foundation |
2018-08-16 | PHASE4 |
| NCT04498273 | TERMINATED | COVID-19 |
Frank C Sciurba |
2020-09-07 | PHASE3 |
| NCT04809818 | COMPLETED | Acute Ischemic Stroke |
Lumosa Therapeutics Co., Ltd. |
2021-03-21 | PHASE1 |
| NCT02369653 | COMPLETED | Lymphoma; Acute Lymphoblastic Leukemia |
Bristol-Myers Squibb |
2015-10-22 | PHASE3 |
| NCT04041843 | COMPLETED | Venous Thromboembolism |
New York Medical College |
2017-06-02 | PHASE2 |
| NCT06817811 | COMPLETED | Health |
Dexa Medica Group |
2021-04-15 | PHASE1 |
| NCT03232398 | COMPLETED | Acute Myocardial Infarction; Left Ventricular Thrombosis; Anticoagulants and Bleeding Disorders |
Hadassah Medical Organization |
2018-01-01 | PHASE3 |
| NCT03153150 | COMPLETED | Intracranial Hemorrhages; Intracranial Hemorrhage, Hypertensive; Subarachnoid Hemorrhage; Subdural Hematoma; Intraventricular Hemorrhage; Atrial Fibrillation; Atrial Flutter; Small Vessel Cerebrovascular Disease; Microhaemorrhage |
University of Edinburgh |
2018-03-28 | PHASE3 |
| NCT05841446 | COMPLETED | Healthy |
The Affiliated Hospital of Qingdao University |
2021-03-02 | PHASE1 |
| NCT02565693 | COMPLETED | Cerebral Hemorrhage; Atrial Fibrillation |
UMC Utrecht |
2014-09 | PHASE2 |
| NCT04192552 | UNKNOWN | Atrial Fibrillation |
McMaster University |
2020-01-09 | |
| NCT03839355 | TERMINATED | Atrial Fibrillation |
Mayo Clinic |
2018-12-19 | PHASE3 |
| NCT04128254 | UNKNOWN | Foot Ankle Injuries; Anticoagulants and Bleeding Disorders; Venous Thromboembolism |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2020-01 | PHASE4 |
| NCT03181386 | COMPLETED | Atrial Fibrillation; Periodontal Disease; Hemorrhage |
University of Sao Paulo General Hospital |
2017-05-03 | PHASE3 |
| NCT04788355 | COMPLETED | Complication |
Universidade do Vale do Sapucai |
2020-07-01 | PHASE3 |
| NCT07699796 | COMPLETED | Venous Thrombosis Deep (Limbs); Venous Insufficiency (Chronic)(Peripheral); Varicose Veins Leg; Venous Thrombosis |
Heart, Artery, and Vein Center of Fresno |
2018-03-06 | PHASE4 |
| NCT02633774 | UNKNOWN | Persistent Atrial Fibrillation |
Yonsei University |
2015-11 | |
| NCT02744092 | COMPLETED | Cancer; Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Blood Clot |
Alliance Foundation Trials, LLC. |
2016-12-13 | |
| NCT02664649 | COMPLETED | Symptomatic Aortic Stenosis; Eligible for Transcatheter Aortic Valve Replacement |
Assistance Publique - Hôpitaux de Paris |
2016-08-26 | PHASE3 |
| NCT02946944 | UNKNOWN | Pulmonary Embolism; Intermediate-high Risk; Combination of Oral Anticoagulation Therapy and Sildenafil |
Meshalkin Research Institute of Pathology of Circulation |
2016-10 | PHASE1 |
| NCT04106700 | TERMINATED | Venous Thromboembolism |
Instituto de Investigacion Sanitaria La Fe |
2019-04-12 | PHASE2 |
| NCT02427126 | COMPLETED | Embolic Stroke of Undetermined Source |
University Hospital Tuebingen |
2015-12 | PHASE3 |
| NCT02789917 | COMPLETED | Acute Coronary Syndrome; Atrial Fibrillation; Coronary Artery Disease |
LMU Klinikum |
2016-06 | PHASE4 |
| NCT04191928 | COMPLETED | Pancreas Cancer; DVT; Pulmonary Embolism |
Thomas Jefferson University |
2020-03-03 | PHASE1 |
| NCT04462003 | UNKNOWN | Deep Vein Thrombosis; Malignancy |
Beni-Suef University |
2019-07-03 | PHASE3 |
| NCT01707394 | COMPLETED | Thromboembolism |
Bristol-Myers Squibb |
2013-01-10 | PHASE1 |
| NCT03988842 | TERMINATED | Pulmonary Embolism With Acute Cor Pulmonale; Pulmonary Embolism; Pulmonary Embolism With Pulmonary Infarction; Pulmonary Embolism Subacute Massive; Right Ventricular Dysfunction; Right Ventricular Failure |
Victor Tapson, MD |
2019-07-25 | PHASE4 |
| NCT02295475 | COMPLETED | Antiphospholipid Syndrome; Thrombosis |
Scott C. Woller, MD |
2014-12-10 | PHASE4 |
| NCT04023760 | COMPLETED | Pharmacokinetics; Kidney Transplant; Lung Transplant |
University of Saskatchewan |
2019-06-26 | PHASE4 |
| NCT02829957 | COMPLETED | Venous Thromboembolism; Menstruation |
Indiana University |
2016-09 | PHASE2; PHASE3 |
| NCT02406885 | COMPLETED | Bariatric Surgery; Obesity |
Johns Hopkins University |
2017-07-19 | PHASE4 |
| NCT02378623 | WITHDRAWN | Patent Foramen Ovale; Cardiac Implantable Electronic Device |
Mayo Clinic |
2015-05 | PHASE2 |
| NCT03398434 | WITHDRAWN | Atrial Fibrillation |
Novartis Pharmaceuticals |
2018-10-16 | PHASE2 |
| NCT03594045 | TERMINATED | Heparin-induced Thrombocytopenia; Heparin-induced Thrombocytopenia and Thrombosis |
Massachusetts General Hospital |
2018-12-18 | PHASE2 |
| NCT03310021 | COMPLETED | Bleeding |
Portola Pharmaceuticals |
2017-08-28 | PHASE2 |
| NCT03288454 | COMPLETED | Healthy |
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. |
2017-08-30 | PHASE2 |
| NCT02942407 | COMPLETED | Atrial Fibrillation; End Stage Renal Disease |
Christopher Granger, MD |
2016-12 | PHASE4 |
| NCT03200613 | TERMINATED | Spinal Cord Injuries; Venous Thromboembolism |
McMaster University |
2017-09-01 | PHASE2 |
| NCT02958969 | COMPLETED | Venous Thromboembolism; Multiple Myeloma |
Gregory Piazza |
2018-02-28 | PHASE4 |
| NCT02599532 | COMPLETED | Nephrotic Syndrome; Proteinuria |
University of North Carolina, Chapel Hill |
2017-04-30 | PHASE1 |
| NCT05632445 | COMPLETED | Left Atrial Appendage Occlusion |
DR. XAVIER FREIXA |
2019-05-01 | PHASE4 |
| NCT03590743 | TERMINATED | Deep Vein Thrombosis |
Mayo Clinic |
2019-02-19 | PHASE4 |
| NCT03045406 | COMPLETED | Venous Thromboembolism |
Fadoi Foundation, Italy |
2017-04-13 | PHASE3 |
| NCT02283294 | COMPLETED | Transient Ischemic Attack; Stroke; Atrial Fibrillation |
University of South Florida |
2015-04 | PHASE3 |
| NCT02366871 | COMPLETED | Gynecologic Cancer; Venous Thromboembolism |
University of Colorado, Denver |
2015-04-28 | PHASE2 |
| NCT02889562 | COMPLETED | Coronary Artery Bypass Grafting; Postoperative Atrial Fibrilation; Stroke; Systemic Embolism; Deep Venous Thrombosis |
Sanford Health |
2016-09 | PHASE2; PHASE3 |
| NCT03196349 | TERMINATED | Venous Thromboembolism |
Duke University |
2018-08-01 | PHASE4 |
| NCT02935855 | COMPLETED | Diabetes |
University of Pavia |
2015-09 | PHASE4 |
| NCT02666157 | UNKNOWN | Atrial Fibrillation |
National Cheng-Kung University Hospital |
2016-01 | PHASE4 |
| NCT03136510 | TERMINATED | Coagulation Disorder; Non Valvular Atrial Fibrillation |
Hopital Lariboisière |
2016-09 | |
| NCT02415400 | COMPLETED | Acute Coronary Syndromes |
Bristol-Myers Squibb |
2015-06-04 | PHASE4 |
| NCT03251482 | COMPLETED | VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery |
Janssen Research & Development, LLC |
2017-11-13 | PHASE2 |
| NCT02982590 | COMPLETED | Left Ventricular Thrombosis |
Universiti Sains Malaysia |
2016-11 | PHASE3 |
| NCT02048865 | COMPLETED | Venous Thromboembolism; Cancer |
Ottawa Hospital Research Institute |
2014-03-24 | PHASE2 |
| NCT03456648 | COMPLETED | ESRD; Anticoagulant Toxicity |
Universitaire Ziekenhuizen KU Leuven |
2016-09-25 | PHASE2 |
| NCT03276143 | COMPLETED | Knee Arthroplasty, Total |
Bayer |
2017-09-21 | PHASE2 |
| NCT02809469 | UNKNOWN | Atrial Fibrillation |
Hamilton Health Sciences Corporation |
2016-08 | PHASE2 |
| NCT03509883 | COMPLETED | Healthy Volunteers |
Bristol-Myers Squibb |
2018-04-26 | PHASE1 |
| NCT01884337 | COMPLETED | Anticoagulation |
Bristol-Myers Squibb |
2015-03-24 | PHASE4 |
| NCT02581176 | COMPLETED | Neoplasms; Venous Thrombosis |
University Hospital, Akershus |
2016-04 | PHASE4 |
| NCT02585713 | COMPLETED | Cerebral Vein Thrombosis; Deep Vein Thrombosis; Gonadal Thrombosis; Hepatic Thrombosis; Malignant Neoplasm; Mesenteric Thrombosis; Metastatic Malignant Neoplasm; Portal Vein Thrombosis; Pulmonary Embolism; Renal Vein Thrombosis; Splenic Thrombosis; Venous Thromboembolism |
Academic and Community Cancer Research United |
2015-11-20 | PHASE3 |
| NCT02749617 | TERMINATED | Anti-Xa Activity |
University of British Columbia |
2016-08-09 | PHASE2 |
| NCT02559856 | COMPLETED | Venous Thromboembolism |
Ottawa Hospital Research Institute |
2016-05 | PHASE4 |
| NCT01675076 | COMPLETED | Hematoma |
Ottawa Heart Institute Research Corporation |
2013-01 | PHASE3 |
| NCT03083704 | COMPLETED | Bleeding |
Portola Pharmaceuticals |
2017-02-26 | PHASE1 |
| NCT02179177 | TERMINATED | Vaso-occlusive Crisis; Reduction in Hospitalizations; Sickle Cell Disease |
Nirmish Shah |
2015-01 | PHASE3 |
| NCT03083782 | COMPLETED | Venous Thromboembolism; Pharmacokinetics; Healthy |
Thomas Jefferson University |
2017-04-18 | PHASE1 |
| NCT02608099 | COMPLETED | Atrial Fibrillation |
Baim Institute for Clinical Research |
2015-11 | PHASE4 |
| NCT02227550 | COMPLETED | Atrial Fibrillation |
Atrial Fibrillation Network |
2014-12 | PHASE4 |
| NCT02100228 | COMPLETED | Atrial Fibrillation |
Pfizer |
2014-07-14 | PHASE4 |
| NCT02450682 | WITHDRAWN | Atrial Fibrillation |
Mayo Clinic |
2016-02 | PHASE2 |
| NCT02090075 | COMPLETED | Atrial Fibrillation |
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center |
2014-09 | PHASE4 |
| NCT00562289 | COMPLETED | Ischemic Stroke; Patent Foramen Ovale; Atrial Septal Aneurysm; Migraine |
Assistance Publique - Hôpitaux de Paris |
2007-12 | PHASE3 |
| NCT02912234 | COMPLETED | Venous Thromboembolism |
Bristol-Myers Squibb |
2016-09 | PHASE1 |
| NCT02672709 | COMPLETED | End-stage Renal Disease |
Jewish General Hospital |
2016-04 | PHASE4 |
| NCT02066454 | COMPLETED | Myeloma; Venous Thromboembolism |
University Hospital, Grenoble |
2014-06-05 | PHASE3 |
| NCT01884350 | COMPLETED | Non-valvular Atrial Fibrillation |
Bristol-Myers Squibb |
2013-10-15 | PHASE4 |
| NCT01924325 | UNKNOWN | Ischemic Stroke; TIA |
Xijing Hospital |
2014-01 | PHASE2; PHASE3 |
| NCT01758432 | COMPLETED | Healthy Volunteers |
Portola Pharmaceuticals |
2012-12 | PHASE2 |
| NCT02207725 | COMPLETED | Bleeding |
Portola Pharmaceuticals |
2014-03 | PHASE3 |
| NCT02270918 | COMPLETED | Thrombosis |
Thomas Jefferson University |
2014-11 | PHASE1 |
| NCT02080858 | COMPLETED | Atrial Fibrillation; Acute Coronary Syndrome |
Medical University of Vienna |
2014-05 | PHASE1 |
| NCT01780987 | COMPLETED | Deep Vein Thrombosis; Pulmonary Embolism |
Pfizer |
2013-01 | PHASE3 |
| NCT02101112 | COMPLETED | Thrombosis |
Bristol-Myers Squibb |
2014-03 | PHASE1 |
| NCT02074358 | COMPLETED | Anticoagulation |
Bristol-Myers Squibb |
2014-02 | PHASE1 |
| NCT00643201 | COMPLETED | Venous Thrombosis |
Bristol-Myers Squibb |
2008-07 | PHASE3 |
| NCT00633893 | COMPLETED | Venous Thrombosis |
Bristol-Myers Squibb |
2008-05 | PHASE3 |
| NCT01195727 | TERMINATED | Venous Thromboembolism |
Bristol-Myers Squibb |
2011-07-26 | PHASE1 |
| NCT02034591 | COMPLETED | Healthy Subjects |
Bristol-Myers Squibb |
2011-10 | PHASE1 |
| NCT01437839 | COMPLETED | Healthy |
Pfizer |
2011-09 | PHASE1 |
| NCT01340586 | COMPLETED | End Stage Renal Disease |
Bristol-Myers Squibb |
2011-06 | PHASE1 |
| NCT02034578 | COMPLETED | Healthy Volunteers |
Bristol-Myers Squibb |
2011-07 | PHASE1 |
| NCT00412984 | COMPLETED | Atrial Fibrillation; Atrial Flutter |
Bristol-Myers Squibb |
2006-12-31 | PHASE3 |
| NCT00457002 | COMPLETED | Venous Thrombosis; Pulmonary Embolism |
Bristol-Myers Squibb |
2007-06 | PHASE3 |
| NCT00831441 | TERMINATED | Acute Coronary Syndrome |
Bristol-Myers Squibb |
2009-03 | PHASE3 |
| NCT00852397 | TERMINATED | Acute Coronary Syndrome |
Pfizer |
2009-04 | PHASE2 |
| NCT00496769 | COMPLETED | Atrial Fibrillation |
Bristol-Myers Squibb |
2007-08-31 | PHASE3 |
| NCT02034565 | COMPLETED | Healthy Volunteers |
Bristol-Myers Squibb |
2010-02 | PHASE1 |
| NCT00423319 | COMPLETED | Deep Vein Thrombosis; Pulmonary Embolism |
Bristol-Myers Squibb |
2007-03 | PHASE3 |
| NCT00787150 | COMPLETED | Atrial Fibrillation |
Pfizer |
2008-06 | PHASE2 |
| NCT00914641 | COMPLETED | Thrombosis |
Pfizer |
2009-06 | PHASE1 |
| NCT00320255 | COMPLETED | Thrombosis; Cancer; Pulmonary Embolism |
Bristol-Myers Squibb |
2006-06 | PHASE2 |
| NCT00452530 | COMPLETED | Deep Vein Thrombosis; Pulmonary Embolism |
Bristol-Myers Squibb |
2007-06 | PHASE3 |
| NCT00371683 | COMPLETED | Deep Vein Thrombosis; Pulmonary Embolism |
Bristol-Myers Squibb |
2006-11 | PHASE3 |
| NCT00313300 | COMPLETED | Acute Coronary Syndrome (ACS) |
Bristol-Myers Squibb |
2006-05 | PHASE2 |
| NCT02262533 | COMPLETED | N/A - Healthy Subjects |
Bristol-Myers Squibb |
2007-06 | PHASE1 |
| NCT00252005 | COMPLETED | Deep-Vein Thrombosis |
Bristol-Myers Squibb |
2005-11 | PHASE2 |
| NCT02262520 | COMPLETED | N/A - Healthy Subjects |
Bristol-Myers Squibb |
2006-01 | PHASE1 |
| NCT00097357 | COMPLETED | Venous Thrombosis; Pulmonary Embolism |
Bristol-Myers Squibb |
2004-10 | PHASE2; PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-02-05)
Check the
Apixaban
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
Note: Technical data last updated: Sep 1, 2026.